About SYNIMMUNE
SYNIMMUNE is a company based in Tubingen (Germany) founded in 2010 was acquired by VERAXA in December 2023.. SYNIMMUNE operates in a competitive market with competitors including Jazz Pharmaceuticals, Blueprint Medicines, PureTech Health, Deciphera and Exelixis, among others.
- Headquarter Tubingen, Germany
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of SYNIMMUNE
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SYNIMMUNE
SYNIMMUNE has secured backing from 1 investor. Prominent investors backing the company include VERAXA. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibody therapeutics for cancer treatment are developed via microfluidic screening.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SYNIMMUNE
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SYNIMMUNE
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Synimmune Comparisons
Competitors of SYNIMMUNE
SYNIMMUNE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Blueprint Medicines, PureTech Health, Deciphera and Exelixis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Type 2 kinase inhibitors for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Synimmune
Frequently Asked Questions about SYNIMMUNE
When was SYNIMMUNE founded?
SYNIMMUNE was founded in 2010.
Where is SYNIMMUNE located?
SYNIMMUNE is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
What does SYNIMMUNE do?
SYNIMMUNE was founded in 2010 as a spin-off from the University of Tübingens Department of Immunology. Early-stage development of mono- and bispecific antibodies targets cancer therapies, with operations based in Tübingen, Germany. Over 6.4 million in grants has been secured from the German Ministry of Education and Research. The pipeline includes two FLT3-targeted candidates: FLYSYN, a chimeric IgG1 antibody in Phase 1, and TACSYN, a bispecific antibody in Phase 2.
Who are the top competitors of SYNIMMUNE?
SYNIMMUNE's top competitors include Jazz Pharmaceuticals, Juno Therapeutics and Deciphera.
Who are SYNIMMUNE's investors?
SYNIMMUNE has 1 investor. Key investors include VERAXA.